Sangamo Biosciences (SGMO) Tops Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Oil rally pressures S&P, Nasdaq; Microsoft, Salesforce buoy Dow
- Oil prices rise 2% as attacks on Saudi Arabia overshadow Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Lumentum shares fall after hitting 52-week high
BMO Capital Starts Sangamo BioSciences (SGMO) at Outperform
April 22, 2015 4:31 PM EDTBMO Capital initiates coverage on Sangamo BioSciences (NASDAQ: SGMO) with a Outperform rating and a price target of $19.00.
Analyst Jim Birchenough commented, "Our favorable outlook is based on its novel and proprietary approach to gene editing, a deep pipeline of gene therapy opportunities with competitive advantage,... More



